131 related articles for article (PubMed ID: 9129142)
1. A mutant Rel-homology domain promotes transcription by p50/NFkappaB1.
Xu X; Gélinas C
Oncogene; 1997 Apr; 14(13):1521-30. PubMed ID: 9129142
[TBL] [Abstract][Full Text] [Related]
2. NFE, a new transcriptional activator that facilitates p50 and c-Rel-dependent IgH 3' enhancer activity.
Linderson Y; Cross D; Neurath MF; Pettersson S
Eur J Immunol; 1997 Feb; 27(2):468-75. PubMed ID: 9045919
[TBL] [Abstract][Full Text] [Related]
3. Tax protein of HTLV-1 interacts with the Rel homology domain of NF-kappa B p65 and c-Rel proteins bound to the NF-kappa B binding site and activates transcription.
Suzuki T; Hirai H; Yoshida M
Oncogene; 1994 Nov; 9(11):3099-105. PubMed ID: 7936632
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the transcription factor NF-kappaB during human mononuclear phagocyte differentiation to macrophages and dendritic cells.
Ammon C; Mondal K; Andreesen R; Krause SW
Biochem Biophys Res Commun; 2000 Feb; 268(1):99-105. PubMed ID: 10652220
[TBL] [Abstract][Full Text] [Related]
5. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
6. Members of the NF-kappaB family expressed in zones of active neurogenesis in the postnatal and adult mouse brain.
Denis-Donini S; Caprini A; Frassoni C; Grilli M
Brain Res Dev Brain Res; 2005 Jan; 154(1):81-9. PubMed ID: 15617758
[TBL] [Abstract][Full Text] [Related]
7. Structure of NF-kappa B p50 homodimer bound to a kappa B site.
Ghosh G; van Duyne G; Ghosh S; Sigler PB
Nature; 1995 Jan; 373(6512):303-10. PubMed ID: 7530332
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA.
Chen FE; Huang DB; Chen YQ; Ghosh G
Nature; 1998 Jan; 391(6665):410-3. PubMed ID: 9450761
[TBL] [Abstract][Full Text] [Related]
9. Structure of the NF-kappa B p50 homodimer bound to DNA.
Müller CW; Rey FA; Sodeoka M; Verdine GL; Harrison SC
Nature; 1995 Jan; 373(6512):311-7. PubMed ID: 7830764
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the kinetics and thermodynamics of transcription factor NF-kappaB homodimerisation.
Day YS; Bacon SL; Hughes-Thomas Z; Blackburn JM; Sutherland JD
Chembiochem; 2002 Dec; 3(12):1192-9. PubMed ID: 12465027
[TBL] [Abstract][Full Text] [Related]
11. Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B.
Kerr LD; Ransone LJ; Wamsley P; Schmitt MJ; Boyer TG; Zhou Q; Berk AJ; Verma IM
Nature; 1993 Sep; 365(6445):412-9. PubMed ID: 8413585
[TBL] [Abstract][Full Text] [Related]
12. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
13. Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation.
Ishikawa H; Asano M; Kanda T; Kumar S; Gélinas C; Ito Y
Oncogene; 1993 Nov; 8(11):2889-96. PubMed ID: 8414493
[TBL] [Abstract][Full Text] [Related]
14. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter.
Thomas RS; Tymms MJ; McKinlay LH; Shannon MF; Seth A; Kola I
Oncogene; 1997 Jun; 14(23):2845-55. PubMed ID: 9190901
[TBL] [Abstract][Full Text] [Related]
15. Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc.
Wolfe SA; Zhou P; Dötsch V; Chen L; You A; Ho SN; Crabtree GR; Wagner G; Verdine GL
Nature; 1997 Jan; 385(6612):172-6. PubMed ID: 8990122
[TBL] [Abstract][Full Text] [Related]
16. Cooperative binding and synergistic activation by RelA and C/EBPbeta on the intercellular adhesion molecule-1 promoter.
Catron KM; Brickwood JR; Shang C; Li Y; Shannon MF; Parks TP
Cell Growth Differ; 1998 Nov; 9(11):949-59. PubMed ID: 9831247
[TBL] [Abstract][Full Text] [Related]
17. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
18. Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB.
Dehbi M; Hiscott J; Pelletier J
Oncogene; 1998 Apr; 16(16):2033-9. PubMed ID: 9572484
[TBL] [Abstract][Full Text] [Related]
19. A biophysical characterisation of factors controlling dimerisation and selectivity in the NF-kappaB and NFAT families.
de Lumley M; Hart DJ; Cooper MA; Symeonides S; Blackburn JM
J Mol Biol; 2004 Jun; 339(5):1059-75. PubMed ID: 15178248
[TBL] [Abstract][Full Text] [Related]
20. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
Nehyba J; Hrdlicková R; Bose HR
Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
